[
    [
        {
            "time": "2018-11-01",
            "original_text": "医药】江琦、赵磊：医药上市公司2018三季报分析：研发创新驱动行业发展，高景气板块持续",
            "features": {
                "keywords": [
                    "医药",
                    "三季报",
                    "研发创新",
                    "高景气板块"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【医药】江琦、赵磊：医药上市公司2018三季报分析：研发创新驱动行业发展，高景气板块持续",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "复星医药:创新研发持续高投入,短期业绩下滑明显",
            "features": {
                "keywords": [
                    "复星医药",
                    "研发投入",
                    "短期业绩下滑"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药:创新研发持续高投入,短期业绩下滑明显",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "复星医药三季报点评:研发投入加大影响当期业绩,生物类似药上市可期",
            "features": {
                "keywords": [
                    "复星医药",
                    "三季报",
                    "研发投入",
                    "生物类似药"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药三季报点评:研发投入加大影响当期业绩,生物类似药上市可期",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]